Ceres Nanosciences

Ceres Nanosciences leverages its groundbreaking Nanotrap® Particle technology to create innovative diagnostic solutions that improve patient outcomes through early disease detection. The company has developed its platform with significant backing from entities like the NIH, DARPA, the Bill & Melinda Gates Foundation, and Schmidt Futures. As a privately held firm, Ceres is positioned to expand its product portfolio across infectious disease, biodefense, and chronic illness diagnostics, collaborating with partners to integrate its technology into critical workflows.

Proprietary Nanotrap® Particle technology that captures, concentrates, and preserves low-abundance analytes (proteins, pathogens, nucleic acids) from biological samples to enable highly sensitive detection for diagnostics and research.

Total raised: $14.6M

Ceres competes with large diagnostic reagent firms (Thermo Fisher, Roche) and specialized sample prep companies. Its differentiation lies in the unique combination of capture, concentration, and preservation offered by the Nanotrap® particles, validated by prestigious funding agencies. Success hinges on proving superior clinical sensitivity and forging partnerships to integrate into mainstream diagnostic workflows.